Gyeonggi-do, South Korea

Minho Yoon


Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Minho Yoon: Innovator in Antibody Development

Introduction

Minho Yoon is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. His innovative work focuses on improving the stability and efficacy of antibodies used in treating autoimmune diseases.

Latest Patents

Minho Yoon holds a patent for an "Anti-FcRn antibody or antigen binding fragment thereof with improved stability." This patent describes an anti-FcRn antibody that binds non-competitively with IgG, resulting in enhanced stability. The invention reduces the production rate of aggregates while maintaining the biological activity necessary for significantly lowering pathogenic autoantibodies in the blood. This advancement has the potential to improve treatment options for autoimmune diseases.

Career Highlights

Throughout his career, Minho Yoon has worked with notable companies in the biotechnology sector. He has been associated with Hanall Biopharma Co., Ltd. and Immunovant Sciences GmbH, where he has contributed to various research and development projects. His expertise in antibody engineering has positioned him as a valuable asset in the industry.

Collaborations

Minho Yoon has collaborated with several professionals in his field, including William Louis Macias and Su Liang. These collaborations have fostered innovation and have led to advancements in antibody research and development.

Conclusion

Minho Yoon's contributions to antibody development and his innovative patent demonstrate his commitment to advancing medical science. His work has the potential to significantly impact the treatment of autoimmune diseases, showcasing the importance of innovation in biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…